Tissue Regenix secures additional coverage in the US for DermaPure

Writer, Stock Market Wire
Thursday, April 4, 2019 - 07:48

Tissue Regenix secured additional coverage with a US Group Purchasing Organization (GPO) for the use of DermaPure, a decellularized allograft dermis.

The company said the additional coverage will open up access to 1,500 hospitals and 32,500 alternative care providers, primarily in the south eastern region of the US, bolstering the commercial opportunity in Florida, the second largest state with regard to the use of biological tissues.

Tissue Regenix said this builds on its contracts with the two largest GPOs in the US, Premier, and Vizient.

The addition of this new agreement increases potential DermaPure availability into 95% of institutions that purchase via large GPO networks, allowing patients and physicians potential to access clinical and health economic benefits provided by DermaPure.


Related content

Tissue Regenix expects to breach revenue loan covenant; in talks with lender

Regenerative medical devices company Tissue Regenix said it was in talks with loan provider MidCap Financial Trust after assessing that it would likely breach on...

Mon, 11/11/2019 - 08:21


Tissue Regenix posts first-half loss; sees better second half

Regenerative medical devices company Tissue Regenix posted a first-half loss but said it expected to post a better performance in the second half owing to...

Tue, 10/09/2019 - 15:02


Tissue Regenix appoints Mike Barker as permanent CFO

Regenerative medical devices company Tissue Regenix said it had appointed Mike Barker as its chief financial officer.

Barker had been assisting the company as interim...

Wed, 28/08/2019 - 07:49


Tissue Regenix signs 10-year lease on facility in US to ramp up processing capacity

Medical devices group Tissue Regenix signed a 10-year lease agreement on a facility to expand processing capacity at its manufacturing base in San Antonio, Texas....

Thu, 15/08/2019 - 08:46


CEO Steve Couldwell resigns from Tissue Regenix due to illness

Regenerative medical devices company Tissue Regenix Group said that CEO Steve Couldwell had resigned his position 'with immediate effect' due to a recurrence of illness....

Thu, 01/08/2019 - 09:45